Cornerstone Capital Management Holdings LLC. boosted its holdings in shares of Insmed Incorporated (NASDAQ:INSM) by 12.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,808 shares of the biopharmaceutical company’s stock after buying an additional 4,600 shares during the period. Cornerstone Capital Management Holdings LLC. owned about 0.05% of Insmed worth $1,272,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in Insmed during the second quarter worth $129,000. BNP Paribas Arbitrage SA lifted its holdings in shares of Insmed by 666.7% during the second quarter. BNP Paribas Arbitrage SA now owns 7,498 shares of the biopharmaceutical company’s stock valued at $129,000 after acquiring an additional 6,520 shares during the period. UBS Asset Management Americas Inc. bought a new position in shares of Insmed during the second quarter valued at $187,000. Virtu KCG Holdings LLC bought a new position in shares of Insmed during the second quarter valued at $201,000. Finally, Redmile Group LLC bought a new position in shares of Insmed during the second quarter valued at $212,000. Hedge funds and other institutional investors own 95.28% of the company’s stock.
Insmed Incorporated (NASDAQ INSM) opened at $31.33 on Friday. The company has a quick ratio of 15.21, a current ratio of 15.21 and a debt-to-equity ratio of 0.13. Insmed Incorporated has a twelve month low of $11.49 and a twelve month high of $32.94. The stock has a market capitalization of $2,450.00, a PE ratio of -10.04 and a beta of 1.19.
A number of research analysts have issued reports on INSM shares. Leerink Swann lifted their price objective on Insmed from $27.00 to $36.00 and gave the company an “outperform” rating in a report on Tuesday, September 5th. HC Wainwright reissued a “buy” rating and set a $35.00 price objective on shares of Insmed in a report on Monday, November 6th. Cowen reissued a “buy” rating and set a $54.00 price objective on shares of Insmed in a report on Friday, November 3rd. Zacks Investment Research cut Insmed from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Finally, ValuEngine raised Insmed from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $34.50.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.com-unik.info/2017/12/24/cornerstone-capital-management-holdings-llc-acquires-4600-shares-of-insmed-incorporated-insm.html.
Insmed Company Profile
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.